EHC Earnings

EHC reported its earnings on 2026-02-05, showcasing a revenue of 1.54B against an estimate of 1.54B, resulting in a 0.3% surprise. The EPS was 1.46, surpassing the expected 1.29 by 13.18% . The stock experienced a 5.86% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following EHC's earnings announcement on 2026-02-05, the stock price moved by 5.86% on the day of the release. Over the subsequent five days, it saw a % change. Historically, EHC's stock price tends to shift by an average of -0.55% in the 10 days leading up to earnings and +3.88% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate EHC’s annual revenue to reach 1.58B, while the EPS is projected at 1.50. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by -0% and EPS estimates No Change by 0% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between EHC's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by -0%, while EPS estimates moved No Change by 0% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, EHC's stock price typically moves by -0.55% in the 10 days before its earnings and +3.88% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of 1.50 and revenue of 1.58B.

The earnings call highlights strong financial performance, including increased free cash flow and reduced labor costs. The company is expanding capacity and sees significant growth potential in inpatient rehabilitation services. Positive trends in managed care volume and strategic initiatives like the Palantir partnership further bolster sentiment. Despite some uncertainties in Medicare Advantage dynamics, the overall outlook remains optimistic, with solid guidance and strategic expansions. The Q&A section reinforces confidence with detailed responses and plans to address challenges. Consequently, a positive stock price movement is expected over the next two weeks.